Hesham Abboud, MD, PhD

September 26, 2022

Ahmed Obeidat, MD, PhD; Benjamin Greenberg, MD; and Hesham Abboud, MD, share their hopes about the evolution of future mutiple sclerosis care and express their gratitude for the next generation of neurologists.

September 26, 2022

Drs Hesham Abboud and Benjamin Greenberg share their excitement for the future of multiple scelrosis treatment and comment on emerging therapies and novel mechanisms of action.

September 26, 2022

Ahmed Obeidat, MD, PhD; Benjamin Greenberg, MD; and Hesham Abboud, MD, discuss their future hopes and concerns for the use of BTK inhibitors in the treatment of multiple sclerosis.

September 19, 2022

Drs Ahmed Obeidat, Hesham Abboud, and Benjamin Greenberg share their experiences with patient compliance and the route of administration of current and emerging therapies for multiple sclerosis.

September 19, 2022

Experts in neurology debate the utility of combination therapy in the management of multiple sclerosis and highlight current obstacles to this treatment approach both in clinical investigation and practice.

September 12, 2022

Ahmed Obeidat, MD, PhD; Benjamin Greenberg, MD; and Hesham Abboud, MD, comment on the need for more inclusive clinical trial patient enrollment criteria, highlighting underserved patient populations.

September 12, 2022

Dr Hesham Abboud shares his opinion on the clinical practicalities of BTKi utilization in patients with multiple sclerosis.

September 06, 2022

Experts in neurology discuss safety concerns and considerations with the use of BTKis in the management of patients with multiple sclerosis.

September 06, 2022

Hesham Abboud, MD, provides insight into the impact of the differnet biochemical compositions of the currently investigated BTKis and highlights on-going clinical trials.

August 29, 2022

Benjamin Greenberg, MD, hypthothezies on where BTK inhibitors fit into the current treatment algorithim for the management of patients with multiple sclerosis.